Mallinckrodt pursues core quest with Questcor merger
This article was originally published in Scrip
Executive Summary
Just nine months after spinning out from Covidien, Mallinckrodt is maintaining its ambition to grow its speciality pharma business aggressively with the planned $5.6bn merger with Questcor Pharmaceuticals. The announcement came only weeks after Mallinckrodt closed its $1.3bn acquisition of Cadence Pharmaceuticals (www.scripintelligence.com, 12 February 2014) and continues to fulfil the commitment Mark Trudeau, Mallinckrodt’s president and CEO, made to investors and analysts last fall.
You may also be interested in...
NuVasive Replaces CFO In Wake Of Poor Q2
Spine firm NuVasive has named Rajesh Asarpota as the company's new executive vice president and chief financial officer. He steps in after the previous CFO left following NuVasive's disappointing Q2 2017 results.
AI Firm Healx Raises $56M To Develop Affordable Rare Disease Treatments
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Abalos Raises €12M Series A To Develop Arenavirus-Based Cancer Therapies
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.